| 前收市價 | 45.17 |
| 開市 | 48.18 |
| 買盤 | 44.33 x 300 |
| 賣出價 | 44.56 x 100 |
| 今日波幅 | 44.18 - 45.19 |
| 52 週波幅 | 44.18 - 77.32 |
| 成交量 | |
| 平均成交量 | 971,885 |
| 市值 | 8.081B |
| Beta 值 (5 年，每月) | 0.01 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.94 |
| 業績公佈日 | 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 86.16 |
ZacksFDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
ZacksWhy Legend Biotech (LEGN) Stock Might be a Great Pick
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Insider MonkeyShould You Continue to Hold Legend Biotech Corporation (LEGN)?
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Optimism started to prevail, during the last months of the year, and investors reacted positively to news of a potential change in direction by the US Federal Reserve, as well as […]
